| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 1.30 | 170.8% |
| Total Income | 1.30 | 170.8% |
| Expenditure | 1.75 | 42.3% |
| PBT | — | |
| Net Profit | -0.62 | 17.3% |
| OPM | -34.29% | |
| NPM | -47.50% | |
| EPS | -0.01 | 50.0% |
Nuo Therapeutics Announces First Quarter 2026 Financial Results
15 May 2026 · 15 May, 2:46 am
Summary
Nuo Therapeutics announced its financial results for the first quarter ended March 31, 2026. Total revenues reached approximately $1.3 million, including product revenues of approximately $1,224,000, which represents a 169% increase over the first quarter of 2025. Aurix branded product revenues were up over 30% sequentially versus the fourth quarter of 2025. The net operating loss was approximately $446,000, an improvement compared to the $745,000 loss in the same period last year.
Key Highlights
- 1
Nuo Therapeutics reported total revenues of approximately $1.3 million for the first quarter of 2026.
- 2
Product revenues were approximately $1,224,000, representing a 169% increase over the 2025 first quarter.
- 3
Aurix branded product revenues increased over 30% sequentially compared to the fourth quarter of 2025.
- 4
The net operating loss for the first quarter of 2026 was approximately $446,000, compared to a net operating loss of approximately $745,000 in the first quarter of 2025.
- 5
The company entered into a Loan and Security Agreement with initial fundings of $1.0 million to provide working capital.
Management Comments
David Jorden
Just over one year ago, Nuo issued our most recent press release and announced the exclusive private label distribution agreement with Smith+Nephew. It would be an understatement to describe the past 12 months and most particularly the first several months of 2026 in the advanced wound care market as anything other than dramatic. Fortunately, we have in Aurix, and Smith+Nephew has in its private label branded offering, a product which we believe is right for the time and the space. With the January 1st change in reimbursement for skin substitutes, interest in autologous platelet rich plasma (PRP) was immediate and vigorous. The disruption within the wound care market is substantial and has created significant uncertainty for many stakeholders including, of course, the provider community. While we have substantial confidence in the benefits available to patients seeking treatment options for non-healing chronic wounds and the wider system from effective PRP products, the disruption does not come without challenges to Nuo as we also navigate the overall market uncertainty. However, we believe we are very attractively positioned for long term success with potential for strong and attractive growth well into the future. With this financial results release, we are making the commitment to now regularly report on our progress beyond our periodic filings with the US Securities and Exchange Commission. We are enthusiastic about the remainder of 2026 and look forward to sharing future developments and our related results.”
Informational and educational content only. Not investment advice.